|
Measurement, number of patients
|
Non-AKI, n = 65
|
RIFLE-Risk, n = 15
|
RIFLE-Injury, n = 10
|
RIFLE-Failure, n = 10
|
P
-value
|
|---|
|
T0, 0 to 6 hr
| | | | | |
|
uNGAL (ng/ml), n = 59
|
31 (16 to 111)
|
396 (70to 1,250)
|
385 (77 to 1,987)
|
1,873 (484 to 3,936)
|
<0.001
|
|
KIM-1 (ng/ml), n = 59
|
0.11 (0.08 to 0.19)
|
0.18 (0.13 to 0.28)
|
0.10 (0.08 to 0.11)
|
1.2 (0.4 to 3.5)
|
0.004
|
|
T1, 6 to 12 hr
| | | | | |
|
uNGAL (ng/ml), n = 85
|
21 (8 to 116)
|
114 (61 to 420)
|
275 (11 to 4630)
|
2430 (727 to 6000)
|
<0.001
|
|
KIM-1 (ng/ml), n = 85
|
0.11 (0.08 to 0.27)
|
0.10 (0.08 to 0.29)
|
0.12 (0.08 to 0.16)
|
0.35 (0.29 to 1.21)
|
0.018
|
|
T2, 12 to 24 hr
| | | | | |
|
uNGAL (ng/ml), n = 95
|
22 (10 to 98)
|
34 (22 to 200)
|
47 (26 to 1935)
|
979 (301 to 6000)
|
0.001
|
|
KIM-1 (ng/ml), n = 93
|
0.16 (0.08 to 0.28)
|
0.26 (0.11 to 0.56)
|
0.30 (0.12 to 0.41)
|
0.47 (0.26 to 2.15)
|
0.002
|
|
24-hr peak level
| | | | | |
|
uNGAL (ng/ml), n = 100
|
59 (16 to 136)
|
225 (89 to 730)
|
385 (56 to 3938)
|
1495 (387 to 6000)
|
<0.001
|
|
KIM-1 (ng/ml), n = 100
|
0.17 (0.08 to 0.34)
|
0.26 (0.11 to 0.56)
|
0.25 (0.10 to 0.41)
|
0.86 (0.44 to 2.15)
|
0.001
|
-
aAKI, Acute kidney injury; KIM-1, Kidney injury molecule-1; RIFLE, Risk, injury, failure, loss, end-stage renal disease; SCr, Serum creatinine; uNGAL, Urinary neutrophil gelatinase-associated lipocalin. Data are expressed as median (interquartile range). P-values indicate overall comparison of all groups (that is, non-AKI versus Risk versus Injury versus Failure). Intergroup differences were assessed using the Kruskal-Wallis test. RIFLE categories risk, injury and failure were defined as, respectively, serum creatinine (SCr) above 150%, 200% and 300% of the median age-specific SCr reference values.
